StockData
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc. (FULC) stock

FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.71−0.06 (-1.59%)

Close on Nov 16, 2026Market cap $283.06MP/E –Yield –

Fulcrum Therapeutics cash

Cash and short-term investments held at the end of each period.

Fulcrum Therapeutics's cash was $48.47M at Jun 30, 2026. For fiscal 2025 it was $197.53M, up 239.3% from the year before. The highest annual figure on record is $197.53M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$197.53M+239.3%
FY2024Dec 31, 2024$58.21M+127.7%
FY2023Dec 31, 2023$25.56M-27.2%
FY2022Dec 31, 2022$35.10M-0.9%
FY2021Dec 31, 2021$35.41M-37.9%
FY2020Dec 31, 2020$57.05M-41.0%
FY2019Dec 31, 2019$96.71M+32.9%
FY2018Dec 31, 2018$72.80M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$48.47M+13.8%
Q1 FY2026Mar 31, 2026$50.26M+19.2%
Q4 FY2025Dec 31, 2025$197.53M+239.3%
Q3 FY2025Sep 30, 2025$47.08M-35.2%
Q2 FY2025Jun 30, 2025$42.59M-50.9%
Q1 FY2025Mar 31, 2025$42.18M+5.6%
Q4 FY2024Dec 31, 2024$58.21M+127.7%
Q3 FY2024Sep 30, 2024$72.63M+141.5%
Q2 FY2024Jun 30, 2024$86.70M+155.3%
Q1 FY2024Mar 31, 2024$39.95M+15.0%
Q4 FY2023Dec 31, 2023$25.56M-27.2%
Q3 FY2023Sep 30, 2023$30.08M-66.9%
Q2 FY2023Jun 30, 2023$33.97M-15.4%
Q1 FY2023Mar 31, 2023$34.73M+4.3%
Q4 FY2022Dec 31, 2022$35.10M-0.9%
Q3 FY2022Sep 30, 2022$90.94M+38.9%
Q2 FY2022Jun 30, 2022$40.15M-29.3%
Q1 FY2022Mar 31, 2022$33.31M-66.9%
Q4 FY2021Dec 31, 2021$35.41M-37.9%
Q3 FY2021Sep 30, 2021$65.47M-23.2%
Q2 FY2021Jun 30, 2021$56.78M-25.0%
Q1 FY2021Mar 31, 2021$100.75M+297.0%
Q4 FY2020Dec 31, 2020$57.05M-41.0%
Q3 FY2020Sep 30, 2020$85.22M-16.1%
Q2 FY2020Jun 30, 2020$75.72M+52.6%
Q1 FY2020Mar 31, 2020$25.38M-59.4%
Q4 FY2019Dec 31, 2019$96.71M+32.9%
Q3 FY2019Sep 30, 2019$101.60M+22.8%
Q2 FY2019Jun 30, 2019$49.63M+522.1%
Q1 FY2019Mar 31, 2019$62.45M–
Q4 FY2018Dec 31, 2018$72.80M–
Q3 FY2018Sep 30, 2018$82.76M–
Q2 FY2018Jun 30, 2018$7.98M–

More Fulcrum Therapeutics figures

See a number that looks wrong?